On Aug 10, 2016, The English High Court (Patents Court) has ruled in a patent dispute
concerned with the treatment of erectile dysfunction. Actavis and Mylan had
commenced "clear the way" litigation by seeking to revoke Eli Lilly's patent in
order to launch generic versions of its CIALIS (Tadalafil) medicine upon expiry of the
relevant SPC protection (November 2017).
One of Eli Lilly's patents, regarding the dosage regimen of CIALIS (EP(UK) 1,173,181), was found to be valid and infringed. The other patent, regarding microparticulate formulation of the active ingredient (tadalafil) (EP(UK) 1,200,092), was invalid. Both patents are expiring in Apr 2020 and Aug 2020 respectively.
Read the judgement in full at:
http://www.bailii.org/ew/cases/EWHC/Patents/2016/1955.html
One of Eli Lilly's patents, regarding the dosage regimen of CIALIS (EP(UK) 1,173,181), was found to be valid and infringed. The other patent, regarding microparticulate formulation of the active ingredient (tadalafil) (EP(UK) 1,200,092), was invalid. Both patents are expiring in Apr 2020 and Aug 2020 respectively.
Read the judgement in full at:
http://www.bailii.org/ew/cases/EWHC/Patents/2016/1955.html
No comments:
Post a Comment